https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-22 08:50:422026-01-22 08:50:42New global consortium aims to transform antibiotic discovery to counter the growing AMR crisis
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-01-22 08:50:422026-01-22 08:50:42New global consortium aims to transform antibiotic discovery to counter the growing AMR crisis
Resolve M Therapeutics exits from stealth
Unique platform designed to engage pro-resolution responses to…

Infinitopes Expands Seed Financing to $35 Million to Accelerate Clinical Development of Precision Cancer Vaccine
Financing co-led by Octopus Ventures and new investor Amplify…

Women in Life Science Denmark (WiLD) expands Nordic footprint with launch of WiLD Finland
WiLD strengthens Nordic collaboration across Denmark, Finland,…

AMSilk’s bioengineered silk protein yarns debut in Balenciaga Spring 2026 Collection
First commercially available products using AMSilk’s biotech…

Novo Nordisk Foundation grants DKK 5.5 billion to elevate innovation in Denmark and Europe
The Novo Nordisk Foundation has allocated up to DKK 5.5 billion…

AMS: Full Year 2025 Trading Update
~ Strong growth in line with expectations, driven by key surgical…

Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies
Kainova Therapeutics rebrand reflects expanding capabilities…

Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines
– 25+ years of biotherapeutics leadership, including serving…

STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications
8 January 2026, Cambridge, UK, and San Diego, US: STORM Therapeutics…

ViCentra Expands Financing to $98 Million to Accelerate European Commercialization and Ready Next Generation Kaleido Insulin Patch Pump System for U.S. Access
Secures an additional $13 million, bringing the total to…

TECregen Raises CHF 10 Million in Seed Financing and Appoints Dr. Bo Rode Hansen as Chairman
TECregen Raises CHF 10 Million in Seed Financing and Appoints…

Lonza’s Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next‑Generation Bispecific ADCs
Multi-target license agreement grants Sidewinder access to…

Nucleome Therapeutics nominates first preclinical development candidate
First-in-class monoclonal antibody agonist programme for inflammation…

AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board
Seasoned executive with extensive board experience across…

Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation
AP31969 is a novel, first-in-class, oral SK ion channel inhibitor…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York